A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT07123103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Study identification
- NCT ID
- NCT07123103
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 18, 2025 (Actual)
- Primary completion
- Nov 2027 (Estimated)
- Completion
- Feb 2028 (Estimated)
- Last update posted
- Feb 17, 2026
2025 – 2028
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #5 | Rogers | Arkansas | 72758 | Recruiting |
| Exelixis Clinical Site #9 | Los Angeles | California | 90033 | Recruiting |
| Exelixis Clinical Site #6 | Washington D.C. | District of Columbia | 20057 | Recruiting |
| Exelixis Clinical Site #4 | Orlando | Florida | 32827 | Recruiting |
| Exelixis Clinical Site #3 | Grand Rapids | Michigan | 49546 | Recruiting |
| Exelixis Clinical Site #7 | New Brunswick | New Jersey | 08901 | Recruiting |
| Exelixis Clinical Site #2 | Huntersville | North Carolina | 28078 | Recruiting |
| Exelixis Clinical Site #8 | Houston | Texas | 77030 | Recruiting |
| Exelixis Clinical Site #1 | San Antonio | Texas | 78229 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07123103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2026 · Synced Oct 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07123103 live on ClinicalTrials.gov.